Discontinued — last reported Q3 '25
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)
Roivant Sciences Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) increased by 19.4% to $1.49B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 25.6%, from $2.00B to $1.49B. Over 2 years (FY 2022 to FY 2024), Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) shows an upward trend with a 26.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests improved liquidity and capacity for investment or debt repayment, while a decrease may indicate aggressive capital allocation or operational cash burn.
Detailed definition
This represents the total liquidity available to the company, including cash, cash equivalents, and restricted cash bala...
Peer comparison
Consumer staples companies typically maintain moderate cash buffers to manage working capital and dividend obligations.
cash_and_equivalents_total_inclusiveHistorical Data
| Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.69B | $1.42B | $6.69B | $6.55B | $5.69B | $2.03B | $2.00B | $2.73B | $1.25B | $1.25B | $1.49B |
| QoQ Change | — | -15.9% | +369.8% | -2.0% | -13.1% | -64.4% | -1.3% | +36.2% | -54.2% | -0.1% | +19.4% |
| YoY Change | — | — | — | +287.1% | — | +42.6% | -70.1% | -58.4% | -78.1% | -38.5% | -25.6% |
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) at Other Companies
Frequently Asked Questions
- What is Roivant Sciences's total cash, cash equivalents, and restricted cash (inclusive)?
- Roivant Sciences (ROIV) reported total cash, cash equivalents, and restricted cash (inclusive) of $1.49B in Q4 2025.
- How has Roivant Sciences's total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
- Roivant Sciences's total cash, cash equivalents, and restricted cash (inclusive) decreased by 25.6% year-over-year, from $2.00B to $1.49B.
- What is the long-term trend for Roivant Sciences's total cash, cash equivalents, and restricted cash (inclusive)?
- Over 2 years (2022 to 2024), Roivant Sciences's total cash, cash equivalents, and restricted cash (inclusive) has grown at a 26.9% compound annual growth rate (CAGR), from $1.69B to $2.73B.
- What does total cash, cash equivalents, and restricted cash (inclusive) mean?
- The total amount of cash and highly liquid assets the company holds.